La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Nkarta a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Nkarta..

Nkarta (NASDAQ:NKTX) Azioni, Catena delle Opzioni

NKARTA INC

Nkarta

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

ITOS

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Barclays initiates coverage on Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Underweight rating and announces Price Target of $19.

News

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On Albertsons Companies with Underweight Rating, Announces Price Target of $19

WIIM

PINS

Pinterest shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $37 to $45.

Shares of iron ore stocks are trading higher after iron ore prices rebounded above $100.

XYZ: 10% &#x7C; <a href="https://www.benzinga.com/node/46505785">Block Will Replace Hess Corp. In The S&amp;P 500 Effective Prior To The Opening Of Trading On Wednesday, July 23</a>
&nbsp;
GCTK: 105% &#x7C; <a href="https://www.benzinga.com/node/46294234">Glucotrack Repurchases Over 90% Of Series A Warrants From $10M Public Offering, Advancing Capital Strategy And Diabetes Device Development</a>
&nbsp;
HSDT: 89% &#x7C; <a href="https://www.benzinga.com/node/46514848">Helius Medical Reports Outcome From PoNS SRP Supporting Planned FDA Submission Seeking Indication For Gait And Balance Deficit In Patients With Chronic Symptoms Of Stroke Under Current Breakthrough Device Designation</a>

Movers

Trading Ideas

GCTK

HSDT

Market-Moving News for July 21st

CoreWeave, Inc. (Nasdaq: CRWV) ("CoreWeave") announced today that it intends, subject to market and other customary conditions, to offer $1,500 million aggregate principal amount of senior notes due 2031 (the "Notes") in a private offering. The Notes will be guaranteed on a senior unsecured basis by certain wholly-owned subsidiaries of CoreWeave.
CoreWeave intends to use the proceeds from the offering of the Notes for general corporate purposes, including, without limitation, repayment of outstanding indebtedness, and to pay fees, costs and expenses in connection with the offering of the Notes.

Offerings

CRWV

CoreWeave Plans $1.5B Private Debt Offering to Refinance Debt and Fund Corporate Growth

BKV Corp. Executes Agreement With Midstream Energy Company To Develop New Carbon Capture And Sequestration Project At Currently Operating Natural Gas Processing Plant In East Texas

DA Davidson analyst Peter Winter maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Buy and raises the price target from $49 to $52.

DA Davidson Maintains Buy on U.S. Bancorp, Raises Price Target to $52

Increasing 2025 guidance
Roper now expects full year 2025 adjusted DEPS of $19.90 - $20.05, compared to previous guidance of $19.80 - $20.05. The Company increased its full year total revenue growth outlook to ~13%, compared to a previous outlook of ~12%, and continues to expect organic revenue growth of +6 – 7%.
For the third quarter of 2025, the Company expects adjusted DEPS of $5.08 - $5.12.
Roper's guidance includes the impact of the Subsplash acquisition, which is expected to close later this month. The Company's guidance excludes the impact of unannounced future acquisitions or divestitures.

Guidance

CORRECTION: Roper Technologies Raises FY2025 Adj EPS Guidance from $19.80-$20.05 to $19.90-$20.05 vs $19.94 Est; Raises FY2025 Sales Guidance from $7.88B to $7.95B vs $7.86B Est

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Amber International Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBR#NASDAQ">AMBR</a>)</h3>
<ul class="wp-block-list">
<li>On July 7, Amber International announced it filed for a $500 mixed shelf offering. The company's stock fell around 38% over the past month and has a 52-week low of $1.55.</li>
<li>RSI Value: 27.6</li>
<li>AMBR Price Action: Shares of Amber International fell 14.3% to close at $7.28 on Friday.</li>
<li>Edge Stock Ratings: Value at 9.96.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/AMBR"><img loading="lazy" decoding="async" width="443" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071634/image-268.png" alt="" class="wp-image-993459" style="width:292px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071634/image-268.png 443w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071634/image-268-300x127.png 300w" sizes="(max-width: 443px) 100vw, 443px" /></a></figure>
<h3 class="wp-block-heading">FingerMotion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNGR#NASDAQ">FNGR</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On July 15, FingerMotion posted a first-quarter loss of 4 cents per share, versus a year-ago loss of 3 cents per share. &#8220;While topline revenue showed modest movement, with margin pressure driven by evolving business dynamics, we are encouraged by the initial revenue contribution from our Command and Communication platform, as well as the steady buildout of the DaGe and Big Data businesses,&#8221; said Martin Shen, CEO of FingerMotion. The company's stock fell around 21% over the past month and <a href="https://www.benzinga.com/quote/FNGR">has a 52-week low</a> of $1.03.</li>
<li>RSI Value: 27</li>
<li>FNGR Price Action: Shares of FingerMotion fell 1.2% to close at $1.63 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">FNGR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="922" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269.png" alt="" class="wp-image-993460" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269-768x710.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Anterix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>)</h3>
<ul class="wp-block-list">
<li>On June 24, Anterix posted downbeat quarterly sales. The company's stock fell around 19% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/ATEX"> low of $22.50.</a></li>
<li>RSI Value: 27.51</li>
<li>ATEX Ltd Price Action: Shares of Anterix gained 0.3% to close at $22.84 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">ATEX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="897" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270.png" alt="" class="wp-image-993464" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270-768x719.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

AMBR

ATEX

FNGR

Top 3 Tech And Telecom Stocks That Could Blast Off In Q3

JP Morgan analyst Christopher Horvers maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Neutral and raises the price target from $56 to $65.

TSCO

JP Morgan Maintains Neutral on Tractor Supply, Raises Price Target to $65

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Outperform and raises the price target from $86 to $100.

TCBI

Keefe, Bruyette & Woods Maintains Outperform on Texas Capital Bancshares, Raises Price Target to $100

HIGHLIGHTS
<ul>
<li>US$450 million project loan facility secured from new strategic partner Appian Capital Advisory to fund the development and construction of the Cariboo Gold Project in B.C., Canada
<ul>
<li>US$100 million initial draw enables the Company to accelerate project pre-construction activities and materially de-risk the Project</li>
<li>US$350 million in subsequent draws available on a final investment decision subject to certain customary project milestones and conditions precedent</li>
</ul>
</li>
<li>Strong endorsement and cornerstone financing commitment from a leading investment fund, exclusively dedicated to long-term value in the mining space</li>
<li>Initial draw to support an infill drilling campaign, certain detailed engineering, procurement, underground development, operational readiness planning, and other early works activities</li>
<li>Enhances financial flexibility with the planned repayment of its outstanding US$25 million term loan with National Bank, as it advances toward fully funding the construction of Cariboo</li>
</ul>
&nbsp;

Osisko Development Secures $250M Credit Facility For Development And Construction Of Cariboo Gold Project In Central British Columbia

Leerink Swann analyst Mani Foroohar downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform and lowers the price target from $45 to $10.

Downgrades

SRPT

Leerink Swann Downgrades Sarepta Therapeutics to Market Perform, Lowers Price Target to $10

Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) experienced an 8% year-over-year slip in Chinese sales during June.
What Happened: The company experienced a slip in sales as rivals like Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>), Xpeng Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NASDAQ">XPEV</a>), etc. gained in sales, Bloomberg reported <a href="https://www.bloomberg.com/news/articles/2025-07-21/life-atop-china-s-car-market-is-starting-to-look-shaky-for-byd">on</a> Monday.
Analysts from investment banks like Deutsche Bank expect the company to hit 5 million wholesale units in 2025, the report suggests, while Morgan Stanley lowered its projection to 5.3 million.
BYD would need to sell over 560,000 units a month to meet its annual delivery projection for 2025 of 5.5 million units sold, which could prove difficult amid electric vehicle price war scrutiny by the Chinese Communist Party, according to the report. 
However, BYD's overseas sales are on track to reach the 800,000 unit milestone the company set out to deliver this year, with 60% of that figure already achieved by BYD, the report suggests.
Why It Matters: The news comes as BYD has adopted an aggressive pricing strategy in the Chinese market with discounted prices amid fierce competition in the sector, which has <a href="https://www.benzinga.com/news/topics/25/06/45715047/byds-aggressive-pricing-triggers-ev-rat-race-stock-tumbles-authorities-voice-concern">raised concerns within</a> the Chinese government.
Despite scrutiny, BYD released <a href="https://www.benzinga.com/markets/tech/25/07/46187880/tesla-rival-byd-launches-11000-long-range-trim-of-its-best-selling-seagull-ev-as-price-war-heats-up">a long-range version</a> of its best-selling EV, the Seagull EV, for $11,000 in the market, as well as the <a href="https://www.benzinga.com/markets/tech/25/06/45855643/tesla-rival-byd-launches-15000-seal-06-sedan-as-chinas-ev-price-war-heats-up">Seal 06 EV</a> for $15,000 in China.
Elsewhere, BYD's fellow Chinese automakers Zeekr Intelligent Technologies Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) and Neta have been accused of <a href="https://www.benzinga.com/markets/asia/25/07/46512860/tesla-rival-geelys-zeekr-neta-inflated-sales-data-in-china-through-insurance-scheme-amid-zero-mileage-used-cars-row-report">inflating sales data </a>through insurance schemes in the country, according to reports in Chinese state media.
Elsewhere, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has recorded <a href="https://www.benzinga.com/markets/tech/25/07/46409821/tesla-rebounds-in-china-with-12-3k-weekly-registrations-highest-2nd-week-ever">over 12.3k insured registrations</a> for the second week of July, which is a strong rebound for Elon Musk's EV giant after a poor start to the month in China.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46512836/elon-musks-tesla-announces-3-million-model-3-units-sold-worldwide">Elon Musk&#8217;s Tesla Announces 3 Million Model 3 Units Sold Worldwide</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

BYDDF

BYDDY

TSLA

XIACY

XPEV

Tesla Rival BYD's Domestic Sales Slip 8% In June, Analysts Slash Annual Delivery Projections Amid EV Price War Scrutiny

Fiserv's Clover Launches PracticePay To Streamline Healthcare Payments For Small And Medium-Sized Healthcare Providers

Jefferies analyst Brian Tanquilut upgrades Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) from Hold to Buy and lowers the price target from $6.25 to $6.

Upgrades

AVAH

Jefferies Upgrades Aveanna Healthcare Hldgs to Buy, Lowers Price Target to $6

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $28 to $20.

JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $20

Three Democrat-led states have decided to revoke or limit health coverage for immigrants without legal status, a move that could have significant consequences for the affected individuals and the healthcare system at large.
What Happened: The states of&nbsp;California,&nbsp;Illinois and&nbsp;Minnesota&nbsp;have recently made the decision to end or reduce health coverage for immigrants without legal status,&nbsp;<a href="https://apnews.com/article/medicaid-immigrants-california-illinois-minnesota-ice-f43d5681a6e9d45d274790c2eae716ee">reported</a>&nbsp;the Associated Press. This change will affect&nbsp;hundreds of thousands of immigrants.
The programs have proven to be much more costly than initially projected, a significant concern given the states&#8217; current and future multibillion-dollar deficits. As a result, Illinois, Minnesota, and California have opted to cut back on the programs to save money.
Adult immigrants aged 42 to 64 without legal status in Illinois have been cut off from health care, resulting in estimated savings of $404 million. In Minnesota, all adult immigrants have been removed from the state program, saving nearly $57 million. California plans to halt new adult enrollments starting in 2026, projecting savings of over $3 billion over several years.
These cuts — backed by Democratic governors who once championed expanded health coverage for immigrants — are already discouraging people from seeking care, largely out of fear of arrest or deportation.
Health care providers have raised concerns about the effects of these cuts, especially the risk that fear of arrest or deportation may prevent immigrants from seeking medical care. This avoidance of preventive services could ultimately result in higher long-term costs, as more immigrants may require treatment at safety-net hospitals.
See Also: <a href="https://benzinga.com/crypto/cryptocurrency/25/07/46495773/shiba-inu-rallies-10-in-1-week-can-it-go-higher" target="_blank" rel="noreferrer noopener">Shiba Inu Rallies 10% In 1 Week: Can It Go Higher?</a>
Why It Matters: The decision to cut health coverage for immigrants without legal status comes&nbsp;at a time when the&nbsp;Trump administration has been taking steps to tighten immigration policies and enforcement.
Earlier this month, the Trump administration&nbsp;<a href="https://www.benzinga.com/news/politics/25/07/46363638/trump-ends-head-start-program-for-illegal-aliens-moves-to-cut-clinton-era-postsecondary-aid-and-other-federal-benefits">announced</a>&nbsp;that undocumented immigrants would no longer be eligible for various federal programs, including the Head Start program and several other federal benefits and programs. This decision, combined with the recent cuts in health coverage, could have a significant impact on the well-being of immigrants without legal status.
Moreover, the Trump administration&#8217;s decision to&nbsp;share 79 million Medicaid recipients&#8217; private <a href="https://www.benzinga.com/news/legal/25/07/46247689/palantir-reportedly-assisting-trump-administrations-doge-to-compile-americans-personal-data">health data</a> with Immigration and Customs Enforcement (ICE)&nbsp;has sparked legal challenges from several states, including California. The recent cuts in health coverage for immigrants without legal status may further exacerbate the already contentious relationship between the federal government and these states.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46381096/trump-administration-ordered-by-judge-to-stop-immigration-arrests-without-probable-cause-in-southern-california-report">Trump Administration Ordered By Judge To Stop Immigration Arrests Without Probable Cause In Southern California: Report</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Medicaid Cuts In 3 Democrat-Led States Strip Health Coverage From Undocumented Immigrants Amid Budget Crunch

Rogers Communications Upsizes Cash Tender Offers To $1.4B To Purchase Eight Series Of US Dollar Debt Securities

Press Releases

Nkarta to Participate in Upcoming Investor Conference

Earnings

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta to Participate in an Upcoming Investor Conference

General

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nkarta to Participate in March Investor Conferences

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Nkarta to Participate in an April Investor Conference

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Comments

Nkarta

Nkarta (NKTX) Opzioni

Nkarta (NASDAQ:NKTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO